Want to see HK:2135 full AI Analyst Report?
Top Page
Raily Aesthetic Medicine International Holdings Limited
(2135)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$0.12
▲(10.00% Upside)
Action:Reiterated
Date:10/30/26
The score is primarily supported by improved 2025 financial performance (return to profitability and strong free cash flow), but is held back by fragile earnings quality and historical volatility. Technical indicators remain bearish (oversold RSI and negative MACD, with price below the 200-day average), while the low P/E provides a valuation offset.
Positive Factors
2025 Profitability Turnaround
The 2025 recovery shows that the business can restore operating profitability after a difficult period. Improved gross and EBITDA margins provide a stronger base for future earnings, although the durability of this improvement will depend on maintaining demand and controlling costs.
Negative Factors
Thin Net Profitability
A net margin near 1% leaves limited protection against cost increases, weaker demand, or operational setbacks. Even after the margin rebound, small changes in revenue or expenses could materially affect bottom-line results, making sustained earnings growth difficult to establish.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Profitability Turnaround
The 2025 recovery shows that the business can restore operating profitability after a difficult period. Improved gross and EBITDA margins provide a stronger base for future earnings, although the durability of this improvement will depend on maintaining demand and controlling costs.
Read all positive factors
Raily Aesthetic Medicine International Holdings Limited (2135) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$62.39M
Dividend YieldN/A
Average Volume (3M)31.24K
Price to Earnings (P/E)3.9
Beta (1Y)0.63
Revenue Growth36.68%
EPS GrowthN/A
CountryHK
Employees264
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.02
Shares Outstanding557,077,330
10 Day Avg. Volume56,200
30 Day Avg. Volume31,244
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)0.70
Price to Sales (P/S)0.41
P/FCF Ratio2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Raily Aesthetic Medicine International Holdings Limited Business Overview & Revenue Model
Company Description
Raily Aesthetic Medicine International Holdings Limited is an investment holding company primarily engaged in providing a comprehensive range of cosmetic medical services. Its operations are structured into three principal segments: Aesthetic Medi...
Raily Aesthetic Medicine International Holdings Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
62
Positive
Cash Flow
53
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 217.97M | 184.51M | 199.34M | 189.38M | 164.52M | 188.37M |
| Gross Profit | 91.89M | 75.70M | 71.41M | 71.49M | 66.78M | 69.69M |
| EBITDA | 38.29M | 26.97M | -34.29M | -6.03M | 3.89M | -6.00M |
| Net Income | 13.39M | 1.82M | -59.21M | -32.46M | -15.91M | -17.69M |
Balance Sheet | ||||||
| Total Assets | 236.88M | 237.75M | 249.92M | 273.60M | 302.65M | 344.73M |
| Cash, Cash Equivalents and Short-Term Investments | 48.67M | 57.82M | 28.87M | 39.79M | 78.78M | 121.72M |
| Total Debt | 49.84M | 59.18M | 56.37M | 51.78M | 48.22M | 67.45M |
| Total Liabilities | 130.72M | 139.45M | 154.41M | 141.01M | 136.77M | 162.37M |
| Stockholders Equity | 112.18M | 107.88M | 104.13M | 138.12M | 166.08M | 178.22M |
Cash Flow | ||||||
| Free Cash Flow | 1.68M | 32.04M | -38.59M | -10.00M | -21.13M | -18.25M |
| Operating Cash Flow | 27.55M | 34.69M | 6.01M | 8.02M | -2.27M | -2.47M |
| Investing Cash Flow | -17.19M | 1.36M | -12.70M | -26.14M | 558.00K | -82.45M |
| Financing Cash Flow | 2.28M | -7.86M | 19.43M | -10.48M | -25.65M | 11.97M |
Raily Aesthetic Medicine International Holdings Limited Technical Analysis
Neutral
0.11
Price Trends
0.11
Negative
0.11
Negative
0.13
Negative
Market Momentum
>-0.01
Negative
50.65
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2135, the sentiment is Neutral. The current price of 0.11 is above the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.11, and below the 200-day MA of 0.13, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.65 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2135.
Raily Aesthetic Medicine International Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$4.17B | 8.81 | 31.63% | 4.33% | 22.71% | 43.58% | |
54 Neutral | HK$62.39M | 3.94 | 12.17% | ― | 36.68% | ― | |
52 Neutral | HK$1.10B | 78.10 | 0.48% | 1.10% | -3.26% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.03B | 31.06 | 1.27% | ― | ― | ― | |
46 Neutral | HK$60.30M | 64.28 | 19.79% | 7.69% | 6.13% | ― |
* Healthcare Sector Average
HK:2135
Raily Aesthetic Medicine International Holdings Limited
0.11
>-0.01
-5.08%
HK:2373
Beauty Farm Medical & Health Industry, Inc.
16.62
-12.95
-43.79%
HK:3886
Town Health International Medical Group Ltd.
0.16
-0.11
-40.07%
HK:6639
Arrail Group Ltd.
1.83
-0.06
-3.23%
HK:8307
Medicskin Holdings Ltd.
0.15
-0.03
-15.56%
HK:2508
Saint Bella Inc.
2.30
-3.60
-61.02%
Raily Aesthetic Medicine International Holdings Limited Corporate Events
Raily Aesthetic Medicine Cancels All Outstanding Share Options
Aug 31, 2026
Raily Aesthetic Medicine International Holdings Limited has cancelled all 47,276,437 outstanding share options previously granted under its share option scheme, effective 31 August 2026. The move follows a review by the board and remuneration comm...
Raily Aesthetic Medicine Swings to Profit on Strong First-Half Revenue Growth
Aug 28, 2026
Raily Aesthetic Medicine International Holdings Limited reported a sharp improvement in performance for the six months ended 30 June 2026, with revenue rising to RMB114.8 million from RMB84.6 million a year earlier. The group swung to a profit of ...
Raily Aesthetic Medicine Sets Board Meeting to Review Interim Results and Dividend
Aug 17, 2026
Raily Aesthetic Medicine International Holdings Limited has scheduled a board meeting for 28 August 2026 to review and approve the group’s unaudited interim results for the six months ended 30 June 2026. The board will also consider whether ...
Raily Aesthetic Medicine Signals Interim Profit on Strong Aesthetic Services and Equipment Sales
Aug 7, 2026
Raily Aesthetic Medicine International Holdings Limited, a Hong Kong-listed provider of aesthetic medical services and equipment, operates in the fast-growing medical beauty sector in China. The group generates revenue from both clinical aesthetic...
Raily Aesthetic Medicine Shifts Hong Kong Principal Office to Tsim Sha Tsui
Aug 7, 2026
Raily Aesthetic Medicine International Holdings Limited has announced a change to its principal place of business in Hong Kong, effective 7 August 2026. The company will relocate its main Hong Kong office from Tsuen Wan to Unit 02, 5/F, Kimberley ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.